BioCentury | Oct 9, 2020
Deals

Arrowhead gains Takeda firepower as it seeks edge over Dicerna in AAT-associated liver disease

Arrowhead has found a partner in Takeda that could help it compete with Dicerna as the two biotechs advance their RNAi therapies to treat alpha-1 antitrypsin (AAT)-associated liver disease. The deal...
BioCentury | Sep 17, 2020
Product Development

Sept. 16 Quick Takes: AAT deficiency data lift Arrowhead; plus Metacrine’s IPO, Seer spinout and PDUFA dates for Niemann-Pick, burn therapies

Arrowhead gains on AAT deficiency dataArrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) gained nearly $1.4 billion in market cap Wednesday after sharing interim data from four alpha-antitrypsin (AAT) deficiency patients treated with ARO-AAT in the Phase II AROAAT2002...
BioCentury | Apr 17, 2020
Product Development

Vir’s dose response, safety data spur combo studies of Alnylam-partnered HBV therapy

With an eye towards a functional cure for chronic HBV, Vir plans to begin testing its siRNA therapy next half in combination with immune boosters. Phase I/II data unveiled Wednesday showed that VIR-2218 alone led...
BioCentury | Apr 17, 2020
Product Development

Seeking safe microbiome therapies amid COVID-19 crisis

Reports that the novel coronavirus lingers in the stools of COVID-19 patients has put a spotlight on the safety risks of gut microbiome therapies. As researchers sort out whether the virus is capable of fecal...
BioCentury | Mar 18, 2020
Regulation

FDA’s clinical trial guidance stresses patient safety, studies’ integrity amid outbreak

As disruptions begin to mount among biopharmas’ planned or ongoing clinical trials during the COVID-19 outbreak, newly issued FDA guidance clarified the agency’s thinking on how sponsors can ensure participants’ safety and implement modifications to...
BioCentury | Feb 25, 2020
Distillery Therapeutics

Inhibiting necroptosis to treat ischemic stroke

...20-residue peptide or systemic ASIC1A knockout reduced ischemia-induced brain damage as assessed by infarct volume. Aros...
BioCentury | Jan 9, 2020
Company News

Deals with Empirico and Aro to help Ionis bring new targets, tissues to early-stage pipeline

Ionis is turning to two young biotechs to build off the success of its antisense oligonucleotides and expand the reach of its platform. The company announced a pair of deals with Empirico and Aro on...
BioCentury | Dec 20, 2019
Product Development

Pharma spinouts: a snapshot of where and how pharmas spin out their assets

The handoff of innovation to academia is all but complete, with universities and other academic institutions accounting for the origin of about 75% of new companies formed in the last three years. But while pharma...
BioCentury | Nov 27, 2019
Company News

With shares rising on M&A chatter, Arrowhead points to pipeline moves in 2020

Buoyed by news of this week's takeout of Medicines Co., Arrowhead is riding a wave of investor enthusiasm for RNAi therapeutics that has quintupled the company’s share price this year, and has boosted its valuation...
BioCentury | Oct 7, 2019
Company News

Amid management shakeup, Akcea strikes latest antisense deal

Akcea will bank $250 million up front from a new licensing deal with Pfizer, adding to a balance sheet already fattened by a February deal with Novartis for another antisense oligonucleotide program based on Akcea's...
Items per page:
1 - 10 of 48
BioCentury | Oct 9, 2020
Deals

Arrowhead gains Takeda firepower as it seeks edge over Dicerna in AAT-associated liver disease

Arrowhead has found a partner in Takeda that could help it compete with Dicerna as the two biotechs advance their RNAi therapies to treat alpha-1 antitrypsin (AAT)-associated liver disease. The deal...
BioCentury | Sep 17, 2020
Product Development

Sept. 16 Quick Takes: AAT deficiency data lift Arrowhead; plus Metacrine’s IPO, Seer spinout and PDUFA dates for Niemann-Pick, burn therapies

Arrowhead gains on AAT deficiency dataArrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) gained nearly $1.4 billion in market cap Wednesday after sharing interim data from four alpha-antitrypsin (AAT) deficiency patients treated with ARO-AAT in the Phase II AROAAT2002...
BioCentury | Apr 17, 2020
Product Development

Vir’s dose response, safety data spur combo studies of Alnylam-partnered HBV therapy

With an eye towards a functional cure for chronic HBV, Vir plans to begin testing its siRNA therapy next half in combination with immune boosters. Phase I/II data unveiled Wednesday showed that VIR-2218 alone led...
BioCentury | Apr 17, 2020
Product Development

Seeking safe microbiome therapies amid COVID-19 crisis

Reports that the novel coronavirus lingers in the stools of COVID-19 patients has put a spotlight on the safety risks of gut microbiome therapies. As researchers sort out whether the virus is capable of fecal...
BioCentury | Mar 18, 2020
Regulation

FDA’s clinical trial guidance stresses patient safety, studies’ integrity amid outbreak

As disruptions begin to mount among biopharmas’ planned or ongoing clinical trials during the COVID-19 outbreak, newly issued FDA guidance clarified the agency’s thinking on how sponsors can ensure participants’ safety and implement modifications to...
BioCentury | Feb 25, 2020
Distillery Therapeutics

Inhibiting necroptosis to treat ischemic stroke

...20-residue peptide or systemic ASIC1A knockout reduced ischemia-induced brain damage as assessed by infarct volume. Aros...
BioCentury | Jan 9, 2020
Company News

Deals with Empirico and Aro to help Ionis bring new targets, tissues to early-stage pipeline

Ionis is turning to two young biotechs to build off the success of its antisense oligonucleotides and expand the reach of its platform. The company announced a pair of deals with Empirico and Aro on...
BioCentury | Dec 20, 2019
Product Development

Pharma spinouts: a snapshot of where and how pharmas spin out their assets

The handoff of innovation to academia is all but complete, with universities and other academic institutions accounting for the origin of about 75% of new companies formed in the last three years. But while pharma...
BioCentury | Nov 27, 2019
Company News

With shares rising on M&A chatter, Arrowhead points to pipeline moves in 2020

Buoyed by news of this week's takeout of Medicines Co., Arrowhead is riding a wave of investor enthusiasm for RNAi therapeutics that has quintupled the company’s share price this year, and has boosted its valuation...
BioCentury | Oct 7, 2019
Company News

Amid management shakeup, Akcea strikes latest antisense deal

Akcea will bank $250 million up front from a new licensing deal with Pfizer, adding to a balance sheet already fattened by a February deal with Novartis for another antisense oligonucleotide program based on Akcea's...
Items per page:
1 - 10 of 48